on SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma Exceeds Q2 2025 Market Expectations
SCHOTT Pharma AG & Co. KGaA reports that its preliminary figures for the second quarter of 2025 surpass market forecasts. The company anticipates Q2 revenues of EUR 252 million, marking a 10% increase year-over-year at constant currencies. The expected EBITDA stands at EUR 72 million, with a corresponding margin of 28.6%.
These results outstrip the current market consensus of EUR 242 million in revenue and EUR 62 million EBITDA with a 25.5% margin, according to research from Vara. Despite these higher figures, SCHOTT Pharma maintains its existing full-year guidance for fiscal 2025, as previously outlined in December 2024.
Complete details of SCHOTT Pharma's second quarter and first half of 2025 results will be released on May 15, 2025.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SCHOTT Pharma AG & Co. KGaA news